• Newsroom»
  • Alerts»
  • Key FDA Officials Signal Approach to Review of Biosimilar...

Alert

Recommended Alerts

Sign Up For Alerts

A Step Forward: FDA Issues Three Draft Guidance Documents As Part of Efforts to Modernize the 510(k) Notification Pathway

On September 7, 2023, FDA issued three new draft guidance documents intended to strengthen the 510(k) premarket notification pathway for medical devices.

Read More

Key FDA Officials Signal Approach to Review of Biosimilar Products

Practices: FDA Regulatory, Advertising & Promotion, Congressional Investigations & Public Policy, Due Diligence Reviews & Transactional Support, FDA Enforcement Actions & Litigation, Post-Approval Compliance, Regulatory Strategy, Product Development & Product Approvals

Printer-Friendly Version

Cookie Settings